Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal.  All content is subject to the portal’s Community Content Guidelines.

 


What's New in Glafabra's Testing the Waters Campaign

Glafabra
Posted at Aug 7

One month into Testing the Waters. Here's what's changing for month two.

More real faces. Starting this Tuesday, we're introducing you to the people building Glafabra — one team member at a time, starting with our CEO.

DECODE keeps going, but simpler: no more separate answer-comment days later. Each new riddle now opens with last time's answer, right in the post.

And more of Glafabra's actual stor...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

How Is Fabry Disease Inherited? — DECODE No. 10

Glafabra
Posted at Aug 6

(Answer to the question last time on August 3: Pompe disease and Gaucher disease — the same Live-cel platform, one gene swapped in, reaches both.)

Fabry disease runs in families, but not the way most genetic conditions do. One chromosome carries the whole story — and it changes who's affected depending on whether it's inherited from mom or dad.

What inheritance pattern is this? Drop your guess in ...more

Categories: Cell & Gene Therapy  |  Fabry Disease  |  Rare Disease
Tags:

One Platform, Three Rare Diseases — DECODE No. 9

Glafabra
Posted at Aug 3

(Last time: five patients, five years, durable enzyme — the FACTS proof.)

 

Here's the twist we've been building toward. The approach behind Live-cel for Fabry isn't limited to one disease. Swap the corrected gene, keep everything else, and the same platform takes aim at two more inherited enzyme disorders — one that weakens muscle, one that affects the spleen, liver, and bone.

 

Can you...more

Categories: Rare Disease
Tags:
  • 1